PAVmed Inc.
Find Ratings ReportsPAVMED INC's gross profit margin for the third quarter of its fiscal year 2023 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth. PAVMED INC has very weak liquidity. Currently, the Quick Ratio is 0.49 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 583.44% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 0.79 | 0.08 |
EBITDA ($mil) | -14.8 | -22.67 |
EBIT ($mil) | -15.53 | -23.37 |
Net Income ($mil) | -17.67 | -26.13 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 26.41 | 56.79 |
Total Assets ($mil) | 42.02 | 72.47 |
Total Debt ($mil) | 49.91 | 38.53 |
Equity ($mil) | -43.26 | 8.95 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | -124.91 | -2040.79 |
EBITDA Margin | -1870.41 | -29825.0 |
Operating Margin | -1963.08 | -30746.05 |
Sales Turnover | 0.04 | 0.01 |
Return on Assets | -168.01 | -118.32 |
Return on Equity | 0.0 | -961.3 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 0.6 | 1.48 |
Debt/Capital | 7.51 | 0.81 |
Interest Expense | 0.16 | 0.53 |
Interest Coverage | -97.66 | -44.42 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 7.98 | 6.15 |
Div / share | 0.0 | 0.0 |
EPS | -2.4 | -4.35 |
Book value / share | -5.42 | 1.46 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 74974.0 | 470291.0 |
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PAVM NM | Peers 49.88 | PAVM NM | Peers 33.16 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. PAVM's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. PAVM's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
PAVM NM | Peers 24.07 | PAVM NA | Peers 0.91 | |||||||||||||||||||||
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. PAVM's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
PAVM NM | Peers 4.96 | PAVM 26.54 | Peers 126.83 | |||||||||||||||||||||
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. PAVM's P/B is negative making this valuation measure meaningless. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, PAVM is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
PAVM 10.92 | Peers 6.41 | PAVM 168.14 | Peers 8.91 | |||||||||||||||||||||
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. PAVM is trading at a significant premium to its subsector. |
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share. PAVM has a sales growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||